Significance of CSE-1034 (Elores™) in treatment of urinary tract infections due to multi-drug resistant extended spectrum beta-lactamases positive Escherichia Coli

Abstract

Urinary tract infection (UTI) is one of the most common infections of geriatric patients in community acquired and hospital acquired settings. Escherichia coli is usually the most common pathogen responsible for UTI. Antibiotic resistance is the main reason for the failure of therapy, especially in E. coli. Biofilm formation, extended spectrum beta-lactamases and metallo beta-lactamase production, and efflux pump overexpression are the main reasons for antibiotic resistance in E. coli. That’s why management of UTI with multi-drug resistant (MDR) E. coli has always been challenge for the clinicians. We are reporting empiric use of new antibiotic adjuvant entity Elores™ (ceftriaxone/sulbactam/disodium edetate) in the management of UTIs caused by MDR E. coli.